Systemic administration of 3-bromopyruvate reveals its interaction with serum proteins in a rat model

BACKGROUND: 3-bromopyruvate (3-BrPA) is a glycolytic inhibitor that affects cancer cells by targeting energy metabolism. Preclinical reports have established that a 1.75 mM dose of 3-BrPA is effective and sufficient to inhibit tumor growth when administered under a loco-regional approach (intraarter...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunjithapatham, Rani, Geschwind, Jean-Francois H, Rao, Pramod P, Boronina, Tatiana N, Cole, Robert N, Ganapathy-Kanniappan, Shanmugasundaram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728150/
https://www.ncbi.nlm.nih.gov/pubmed/23866825
http://dx.doi.org/10.1186/1756-0500-6-277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728150/
https://www.ncbi.nlm.nih.gov/pubmed/23866825
http://dx.doi.org/10.1186/1756-0500-6-277

Ejemplares similares